Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3/A

KERYX BIOPHARMACEUTICALS INC

Form 3/A

August 04, 2015

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

January 31, 2005

0.5

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement KERYX BIOPHARMACEUTICALS INC [KERX] Holmes Scott A (Month/Day/Year) 07/27/2015 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O KERYX 08/03/2015 (Check all applicable) BIOPHARMACEUTICALS, INC... 750 LEXINGTON 10% Owner Director **AVENUE** _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Chief Financial Officer Filing(Check Applicable Line) _X_ Form filed by One Reporting NEW YORK, NYÂ 10022 Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

Title CO 1

1.Title of Security
(Instr. 4)
2. Amount of Beneficially

2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form:

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Title and Amount of 6. Nature of Indirect 1. Title of Derivative 2. Date Exercisable and 4. 5. **Expiration Date** Securities Underlying Security Conversion Ownership Beneficial (Instr. 4) (Month/Day/Year) **Derivative Security** or Exercise Form of Ownership (Instr. 4) Price of Derivative (Instr. 5) Derivative Security:

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3/A

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Options (Right to Buy)	07/27/2016(1)	07/27/2025	Common	100,000	\$ 7.66 (2)	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Holmes Scott A							
C/O KERYX BIOPHARMACEUTICALS, INC.	Â	â	Chief Financial Officer	â			
750 LEXINGTON AVENUE	А	А	A Cinei Financiai Officei	A			
NEW YORK. NY 10022							

Signatures

/s/ Brian Adams, Attorney-in-Fact 08/04/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The options vest according to the following schedule: one-third of the 100,000 options vest on July 27, 2016, and the remaining shares vest in equal quarterly installments through the third anniversary of the start date on July 27, 2018.
- (2) This Form 3/A is being filed to amend an incorrect stock option exercise price as reported on the original Form 3, filed on August 3, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2